https://www.selleckchem.com/products/ms023.html
05). However, there was a statistically significant difference between the groups in terms of the injection number ( .05). Both ranibizumab and aflibercept were found to be effective on diabetic macular edema in previously vitrectomized eyes. There was no difference between the groups in terms of visual acuity gain and CMT improvement. However, the number of injections was found to be lower in aflibercept group. Therefore, aflibercept may be preferred in the treatment of macular edema in previously vitrectomized eyes. Both ranibizumab
Aimer
Commentaire
Partagez
